ASH 2022

MRD is one of the strongest predictors of outcomes in lymphoid malignancies1-5

The case for clonoSEQ®

clonoSEQ is the only FDA-cleared assay for assessing MRD in lymphoid malignancies.

  • Significant and expanding body of evidence 1,3,6-12
  • Proven peripheral blood testing 9-13
  • Performed on >22,000 unique patients to date
  • Clinically used in all 32 NCCN® Member Institutions14

For information on ordering clonoSEQ, call us at 1 (888) 552-8988.



Quadruplet Induction, Autologous Transplantation and Minimal Residual Disease Adapted Consolidation and Treatment Cessation in Older Adults ≥70y with Newly Diagnosed Multiple Myeloma: A Subgroup Analysis of the Master Trial

Smith Giri, MD, MHS, et al.



Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Alcyone Study

Maria-Victoria Mateos, MD, et al.



Efficacy Outcomes and Characteristics of Patients with Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity after Treatment with Ciltacabtagene Autoleucel (cilta-cel) in CARTITUDE-1

Nikhil C Munshi, MD, PhD, et al.



Prospective Trial Using Multimodal Measurable Residual Disease Negativity to Guide Discontinuation of Maintenance Therapy in Multiple Myeloma (MRD2STOP)

Ben A. Derman, MD, et al.



Needle in a Haystack: A Pilot Study Combining Single-Cell Multiomics with Clinical NGS-MRD Sequencing to Search for Circulating Clonotypic Dedifferentiated Myeloma Cells

Scott R. Goldsmith, MD, et al.



Phase 1 Study of CART-Ddbcma for the Treatment of Subjects with Relapsed and /or Refractory Multiple Myeloma

Matthew Frigault, MD, MS, et al.



Final Results from the First-in-Human Phase 1/2 Study of Modakafusp Alfa, an Immune-Targeting Attenuated Cytokine, in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Dan T. Vogl, MD, et al.



A Real-World Study on the Feasibility of Minimal Residual Disease Testing By Next-Generation Sequencing in Systemic Light-Chain Amyloidosis

Sireesha Asoori, MBBS, MPH, et al.



Early and Sustained Undetectable Measurable Residual Disease (MRD) after Idecabtagene Vicleucel (ide-cel) Defines a Subset of Multiple Myeloma (MM) Patients in Karmma Achieving Prolonged Survival

Bruno Paiva, PharmD, PhD, et al.



Induction Quadruplet Therapy and Minimal/Measurable Residual Disease (MRD)-Informed Treatment Adaptation in Newly Diagnosed Multiple Myeloma (NDMM): Results from an Academic-Community Pathway

Gayathri Ravi, MD, et al.


Product theater

The clinical actionability of clonoSEQ MRD assessment in lymphoid malignancies.

Allison Jacob, MS
Senior Medical Director, Adaptive Biotechnologies

Sunday, Dec. 11
11:30 am – 12:30 pm Central Time
Theater 1 – Exhibit Hall – Halls G-J – Ernest N. Morial Center

Join us for a live presentation with Allison Jacob from Adaptive Biotechnologies as she discusses the latest advances in next-generation sequencing for minimal residual disease (MRD) detection in lymphoid cancers including myeloma, CLL, ALL, and DLBCL.

Not an official event of the 64th ASH Annual Meeting & Exposition. Not sponsored or endorsed by ASH. Not CME-accredited.

Corporate Reception

Join us for an evening of jazz, conversation, and education.

Maison Bourbon
641 Bourbon St
December 10, 2022
8-11 pm Central Time

Maison Bourbon is a 10-minute drive or a 30-minute walk from the Ernest N. Morial Convention Center

clonoSEQ Product Resources

Learn more about clonoSEQ Assay by downloading these helpful resources:

  • clonoSEQ Product Sheet
  • clonoSEQ Coverage
  • Adaptive Assist Brochure
  • Adaptive Assist Brochure – Spanish
  • clonoSEQ
    Clinical Reports One Pager

Connect with Medical Affairs

Request information from a member of our Medical Affairs team.

This page is intended for a US-based audience.

clonoSEQ® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect minimal residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). CLL Clonality (ID) Tests will also produce an IGHV status result, which is provided as a CLIA-validated laboratory developed test (LDT) but which has not been cleared or approved by the FDA. Additionally, clonoSEQ is available for use in other lymphoid cancers and specimen types as a CLIA-validated LDT. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technical-summary.


  • Martinez-Lopez J, et al. J Hematol Oncol. 2021;14(1):126.
  • Friend BD, et al. Pediatr Blood Cancer. 2020;67(2):e28079.
  • Al-Sawaf O, et al. J Clin Oncol. 2021;39(36):4049-4060.
  • Ching T, et al. BMC Cancer. 2020;20(1):612.
  • Thompson PA, et al. Leukemia. 2018;32(11):2388-2398.
  • Al-Sawaf O, et al. Lancet Oncol. 2020;21(9):1188-1200.
  • Short NJ, et al. Am J Hematol. 2019;94:257-265.
  • Wood B, et al. Blood. 2018;131(12):1350-1359.
  • Pulsipher M, et al. Poster presented at: the 60th ASH Annual Meeting and Exposition; December 1-4, 2018; San Diego, California.
  • Muffly L, et al. Blood Adv. 2021;5(16):3147-3151.
  • Sala Torra O, et al. Biol Blood Marrow Transplant. 2017;23(4):691-696.
  • Logan AC, et al. Biol Blood Marrow Transplant. 2014;20(9):1307-1313.
  • Vij R, et al. Clinical Lymphoma, Myeloma & Leukemia. 2014.14(2):131-139.
  • Data on file. Adaptive Biotechnologies. 2021.